According to a Taipei Times report, biomedical company Darfeux (6523) announced its Q3 2026 consolidated revenue at 280 million TWD, down 12% year-over-year, with after-tax net income of 83.14 million TWD and earnings per share of 1.85 TWD. For the first nine months of 2026, consolidated revenue reached 760 million TWD with after-tax net income of 180 million TWD and cumulative EPS of 4.05 TWD.

The board approved a Q3 cash dividend of 2 TWD per share plus a 2 TWD distribution from capital reserves, totaling 4 TWD per share, bringing year-to-date total dividends to 8 TWD.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.